Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, De Ronne C, Verschueren M, Schoefs E, Vanhellemont A, Delforge M, Schjesvold F, Cabezudo E, Vandebroek M, Stevens H, Simoens S, Huys I. What matters most to patients with multiple myeloma? a Pan-European patient preference study. Front Oncol. 2022 Nov 29;12:1027353. doi: 10.3389/fonc.2022.1027353
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Sasane R, Mitra D, Hodgkins P, Davis KL. Childhood ADHD in Europe: a comparison of patient and physician profiles across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S616-7.
Mitra D, Sasane R, Hodgkins P, Davis KL. Management of ADHD among children in Europe: a comparison of practice patterns across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S625-6.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant induced sexual dysfunction in Europe: a preliminary investigation. Eur Neuropsychopharmacol. 2004 Jan 1;14:S180.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X